2023 Fiscal Year Final Research Report
The PARP and ROS signaling pathways in the mechanism of action of anticancer drugs.
| Project/Area Number |
20K07210
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 47060:Clinical pharmacy-related
|
|---|
| Research Institution | Kinjo Gakuin University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 抗がん薬 / PARP阻害薬 |
|---|
| Outline of Final Research Achievements |
PARP and ROS signalling mechanisms in the mechanism of action of anticancer drugs were investigated. The function of PARP was assessed with and without PARP inhibitors (e.g. olaparib). H2O2 (reaction time: 4 h) induced apoptosis and reduced cell viability in HL-60 cells. Pirarubicin (THP) (4 h) reduced cell viability in HL-60 cells and this reduction was not affected by olaparib. In contrast, THP (24 h) reduced cell viability against HL-60 cells, which was inhibited by olaparib. Doxorubicin (DOX) (24 h) reduced cell viability against HL-60 cells, which was enhanced by olaparib. This reduction was potentiated by olaparib.
|
| Free Research Field |
医療系薬学
|
| Academic Significance and Societal Importance of the Research Achievements |
抗がん薬の作用機序におけるPARPと活性酸素（ROS）シグナル伝達機構について検討することにより、抗がん薬の作用機序におけるPARPの働きを明らかにした。PARP, ROS,および関連する分子が抗がん薬治療の新しいバイオマーカーに成り得ることを示唆しており、新しいがん治療標的分子の提案につながり、これらを用いた新しいがん化学療法の開発と創薬への基盤情報となり得る。
|
